The diagnosis and treatment of acromegaly

被引:2
作者
Katznelson, L
机构
[1] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
acromegaly; pegvisomant; pituitary tumor; IGF-I; GH;
D O I
10.1097/01.ten.0000090922.12899.31
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acromegaly is an endocrine disorder that affects multiple organ systems and increases mortality by 2 to 4 times that of the general population. Elevated growth hormone (GH) levels are the hallmark of acromegaly, but GH secretion is pulsatile and not an accurate marker of disease. IGF-I provides a reliable indication of overall GH secretion and is the single most reliable screening test for acromegaly. In addition, many of the somatotrophic effects of GH are mediated by IGF-I. The goals of treatment of acromegaly are to achieve biochemical control, stabilize or reduce tumor size, and maintain or recover pituitary function. Treatment options for acromegaly include surgery, radiation therapy, and drug therapy. Available medical therapies include somatostatin analogs and dopamine agonists. The advantages and limitations of these therapies are reviewed. A novel medical therapy is pegvisomant, a GH receptor antagonist that binds to GH receptors on the cell surface of target cells and blocks GH signal transduction and GH action. Unlike other medical therapies, effectiveness of pegvisomant is independent of receptor expression on pituitary tumors. Pegvisomant has been demonstrated to be highly effective in reducing IGF-I concentrations to normal levels and significantly improving signs and symptoms of acromegaly in up to 97% of treated patients. Therefore, pegvisomant is a promising new agent that offers significant advances in the treatment of acromegaly.
引用
收藏
页码:428 / 434
页数:7
相关论文
共 50 条
  • [21] Pegvisomant in the treatment of acromegaly
    Parkinson, C
    Scarlett, JA
    Trainer, PJ
    ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (10) : 1303 - 1314
  • [22] Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly
    Laure Cazabat
    Jean-Claude Souberbielle
    Philippe Chanson
    Pituitary, 2008, 11 : 129 - 139
  • [23] Lanreotide for the treatment of acromegaly
    Castinetti, F.
    Saveanu, A.
    Morange, I.
    Brue, T.
    ADVANCES IN THERAPY, 2009, 26 (06) : 600 - 612
  • [24] An update on the treatment of acromegaly
    Edling, Kari L.
    Heaney, Anthony P.
    RESEARCH AND REPORTS IN ENDOCRINE DISORDERS, 2013, 3 : 1 - 11
  • [25] Treatment of acromegaly - data from the German Acromegaly Register
    Toenjes, Anke
    Quinkler, Marcus
    Knappe, Ulrich
    Stoermann, Sylvere
    Schoefl, Christof
    Schopohl, Jochen
    Meyhoefer, Sebastian M.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (07) : 380 - 385
  • [26] Consensus on criteria for acromegaly diagnosis and remission
    Giustina, Andrea
    Biermasz, Nienke
    Casanueva, Felipe F.
    Fleseriu, Maria
    Mortini, Pietro
    Strasburger, Christian
    van der Lely, A. J.
    Wass, John
    Melmed, Shlomo
    PITUITARY, 2024, 27 (01) : 7 - 22
  • [27] Real World Data on the Epidemiology, Diagnosis, and Treatment of Acromegaly: A Registries-based Approach
    Kerbel, Jacobo
    Cano-Zaragoza, Amayrani
    Espinosa-Dorado, Rodrigo
    de la Torre, Keren-Enid Garcia
    Mercado, Moises
    ARCHIVES OF MEDICAL RESEARCH, 2023, 54 (06)
  • [28] Real-world value of cabergoline in the treatment of acromegaly
    Shimon, Ilan
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 38 (04)
  • [29] Acromegaly at diagnosis in 3173 patients from the Liege Acromegaly Survey (LAS) Database
    Petrossians, Patrick
    Daly, Adrian F.
    Natchev, Emil
    Maione, Luigi
    Blijdorp, Karin
    Sahnoun-Fathallah, Mona
    Auriemma, Renata
    Diallo, Alpha M.
    Hulting, Anna-Lena
    Ferone, Diego
    Hana, Vaclav, Jr.
    Filipponi, Silvia
    Sievers, Caroline
    Nogueira, Claudia
    Fajardo-Montanana, Carmen
    Carvalho, Davide
    Hana, Vaclav
    Stalla, Guenter K.
    Jaffrain-Rea, Marie-Lise
    Delemer, Brigitte
    Colao, Annamaria
    Brue, Thierry
    Neggers, Sebastian J. C. M. M.
    Zacharieva, Sabina
    Chanson, Philippe
    Beckers, Albert
    ENDOCRINE-RELATED CANCER, 2017, 24 (10) : 505 - 518
  • [30] Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly
    Witek, Przemyslaw
    Mucha, Slawomir
    Ruchala, Marek
    ENDOKRYNOLOGIA POLSKA, 2016, 67 (06) : 572 - 579